MYD88 and primary central nervous system lymphoma: Targeted NGS of plasma-derived ctDNA in patients with PCNSL has shown a sensitivity of 45% in detecting mutations present in the primary tumor tissue, particularly in genes involved in the B-cell receptor signaling pathway, including MYD88, PIM1, and CD79 [95,96].